40 Million Covid Shots Remain Unused in Philippines Over ‘Logistical Bottlenecks’
(Bloomberg) -- Millions of coronavirus vaccines remain unused in the Philippines as logistical bottlenecks and hesitancy slow inoculations, health officials said, highlighting another risk to the nation's economic recovery.
More than 40 million of the 108 million vaccines the nation has received are in warehouses, in transit to the archipelago's remote islands, or waiting to be used in local health offices, according to the health department. Inoculations are hampered by “logistical bottlenecks,” Health Secretary Francisco Duque said at a virtual briefing Wednesday.
Health workers, who administer shots, were infected, while some local governments took their time with inoculations thinking it's “business as usual,” Undersecretary Myrna Cabotaje said at a separate briefing. Vaccine hesitancy also continues to be a roadblock, with as many as a quarter of the population doubting Covid-19 shots, she said.
Philippines Still Worst Place in Covid Even as Cases Ease Off
The Philippines, which lags much of Southeast Asia in terms of vaccine coverage, stayed at the bottom of Bloomberg's Covid Resilience Ranking last month despite decreasing infections. Even with only a quarter of the population fully vaccinated, the government has eased movement restrictions, allowing gyms and cinemas to reopen to help boost a nascent economic recovery.
The government will push local governments to quicken rollout, and will raffle off cash prizes to encourage the public to get vaccinated, Cabotaje said.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.